arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Mereo BioPharma Group plc

MREO

$0.30 ▼ -0.02 (-5.18%) at close

5 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Mereo BioPharma Group plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $239.1M

Dividend Yield —

Revenue Growth —

Op. Margin None

ROIC -98.0% ↘

FCF / Share $-0.04 ↗

Trailing P/E —

Price / Book 5.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$500.00K

— —

Net Income Profit after all expenses

$-41.88M

↑ +3.2% —

FCF / Share Free cash flow per share

$-0.04

↑ +12.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
EPS Growth YoY (%)	16.7% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-50.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	42.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	3.2% Caution ↑ Caution Improving Year-over-year change in net income	-46.8% Weak Weak Year-over-year change in net income	30.2% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	12.4% Fair ↑ Fair Improving Year-over-year change in free cash flow	-38.5% Weak Weak Year-over-year change in free cash flow	60.4% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Operating Margin (%) (%)	—	—	-284.2% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1994%)	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	-294.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2556%)	—	—
FCF Margin (%) (%)	—	—	-211.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.16x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-98.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-77.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-55.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-104.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-87.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-62.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-70.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-102.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-782%)	-70.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-573%)	-58.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-489%)	-82.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-648%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Interest Coverage (x)	-157.28x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-34.57x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-9.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	-13.04x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-40.99M	$-69.80M	$-57.42M	$-68.18M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.02	$0.00	—
Basic EPS, GAAP (USD)	$-0.05	$-0.06	$-0.04	$-0.07	—
Free Cash Flow per Share (USD)	$-0.04	$-0.04	$-0.03	$-0.08	—
Book Value per Share (USD)	$0.05	$0.08	$0.08	$0.09	—
Tangible Book Value per Share (USD)	$0.05	$0.08	$0.07	$0.09	—
Basic Weighted Avg Shares (shares)	797.12M	739.62M	659.45M	603.20M	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$40.72M	$60.91M	$54.27M	$50.82M	—
Total Equity (USD)	$40.92M	$60.97M	$50.54M	$51.40M	$92.20M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$500.00K	$0.00	$10.00M	$0.00	—
Depreciation Expense (USD)	$157.00K	$143.00K	$171.00K	$181.00K	—
Net Income, GAAP (USD)	$-41.88M	$-43.25M	$-29.47M	$-42.22M	—
Operating Cash Flow (USD)	$-30.97M	$-32.83M	$-21.13M	$-48.82M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 15 quarters

Mereo BioPharma Group plc

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MREO with peers